TNFRSF17 and Miyoshi myopathy: Despite lower expression of BCMA in AL PCs when compared to MM controls, ex vivo validation studies confirmed efficient targeting of these cells by HBI0101/NXC-201 CART cells, and an initial 4 [77] and subsequently a total of 11 AL amyloidosis patients out of a target 40 have been treated to date with HBI0101/NXC-201 CART.